Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Virtual Conference 2021 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#571 Safety and Efficacy of Peptide Receptor Radionuclide Therapy after Liver Transplantation in Metastatic Neuroendocrine Tumors

Introduction: Liver transplantation is an important option for patients of neuroendocrine tumors (NET) with metastases limited to the liver. Peptide receptor radionuclide therapy (PRRNT) is effective in the management of metastatic NET.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Kulkarni H, Kaemmerer D, Hoersch D, Hommann M, Baum R,

Keywords: liver transplantation, peptide receptor radionuclide therapy,

#567 Efficacy of Combined Peptide Receptor Radionuclide Therapy and Radiofrequency Ablation for the Management of Hepatic Metastases of Neuroendocrine Tumors

Introduction: Hepatic metastases significantly affect the overall prognosis and quality of life in patients with gastroenteropancreatic neuroendocrine tumours (GEP-NET). Radiofrequency ablation (RFA) is one of the important local ablative strategies for hepatic metastases. Peptide receptor radionuclide therapy (PRRNT) is a well-established therapeutic modality for metastatic NET.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Kulkarni H, Kaemmerer D, Petrovich A, Hoersch D, Hommann M,

Keywords: Peptide receptor radionuclide therapy, radiofrequency ablation,

#563 Role of Ga-68 Somatostatin Receptor PET/CT in the Assessment of Response to Radiofrequency Ablation in Hepatic Metastases of Neuroendocrine Tumors

Introduction: Patients with gastroenteropancreatic neuroendocrine tumors (GEP-NET) present frequently with hepatic metastases. Radiofrequency ablation (RFA) is an important local ablative treatment for hepatic metastases.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Kulkarni H, Kaemmerer D, Petrovich A, Hoersch D, Baum R,

Keywords: Somatostatin Receptor PET/CT, radiofrequency ablation, hepatic metastases,

#334 Everolimus + Octreotide LAR v. Placebo + Octreotide LAR in Patients With Advanced NET: Results of a Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Trial (RADIANT-2)

Introduction: Everolimus, an oral inhibitor of mTOR, demonstrated promising antitumor activity in patients with NET as a single agent and in combination with octreotide LAR in two phase 2 studies.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Pavel M, Peeters M, Höersch D, Van Cutsem E, Öberg K,

Keywords: mTOR, everolimus, octreotide LAR, neuroendocrine tumor,

#242 Ga-68 SMS-R PET/CT in the Detection of Unknown Primary Neuroendocrine Tumor- Single Centre Result in 124 Patients

Introduction: Ga-68 Somatostatin-Receptor PET/CT (R-PET/CT) has been reported to be superior to In-111 octreoscan in the detection of unknown primary of neuroendocrine tumors (CUP-NET) (EJNMMI 2010 Jan;37(1):67-77)

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Prasad V, Hommann M, Settmacher U, Kaemmerer D, Hoersch D,

Keywords: CUP NET, Ga-68 SMS-R PET/CT,

Abstract Submissions in 2022

Abstract submissions for 2022 will open in September 2021!

 

The 19th Annual ENETS Conference in 2022 will provide the principal platform for NET researchers around the world to present their latest findings. ENETS will select the best abstracts submitted in both clinical and basic science and present these in sessions within the framework of its scientific programme.

 

Participants of the ENETS Virtual Conference 2021 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

Membership matters

Multidisciplinary is our credo. We welcome all NET-related disciplines and professionals! Learn more about the benefits of becoming an ENETS member.